A human monoclonal antibody that specifically binds and inhibits the staphylococcal complement inhibitor protein SCIN

Hedzer Hoekstra, Francisco Romero Pastrana, Hendrik P. J. Bonarius, Kok P. M. van Kessel, Goffe Elsinga, Neeltje Kooi, Herman Groen, Jan Maarten van Dijl, and Girbe Buist

*Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; †IQ Therapeutics, Groningen, The Netherlands; ‡Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands

**ABSTRACT**

*Staphylococcus aureus* is a serious public health burden causing a wide variety of infections. Earlier detection of such infections could result in faster and more directed therapies that also prevent resistance development. Human monoclonal antibodies (humAbs) are promising tools for diagnosis and therapy owing to their relatively straightforward synthesis, long history of safe clinical use and high target specificity. Here we show that the humAb 6D4, which was obtained from a random screen of B-cells producing antibodies that bind to whole cells of *S. aureus*, targets the staphylococcal complement inhibitor (SCIN). The epitope recognized by 6D4 was localized to residues 26 to 36 in the N-terminus of SCIN, which overlap with the active site. Accordingly, 6D4 can inhibit SCIN activity as demonstrated through the analysis of C3b deposition on *S. aureus* cells and complement-induced lysis of rabbit erythrocytes. Importantly, while SCIN is generally regarded as a secreted virulence factor, 6D4 allowed detection of strongly increased SCIN binding to *S. aureus* cells upon exposure to human serum, relating to the known binding of SCIN to C3 convertases secreted virulence factor, 6D4 allowed detection of strongly increased SCIN binding to *S. aureus* cells upon exposure to human serum, relating to the known binding of SCIN to C3 convertases deposited on the staphylococcal cell surface. Lastly, we show that labeling of humAb 6D4 with a near-infrared fluorophore allows one-step detection of SCIN-producing *S. aureus* cells. Together, our findings show that the newly described humAb 6D4 specifically recognizes *S. aureus* SCIN, which can potentially be used for detection of human serum-incubated *S. aureus* strains expressing SCIN.

**Introduction**

*Staphylococcus aureus* is a highly adaptable and dangerous Gram-positive bacterial pathogen that is asymptptomatically carried by about one-third of the human population. *S. aureus* can cause a wide variety of infections due to its extensive arsenal of virulence factors. A subset of these virulence factors target the human immune system by blocking chemotaxis of phagocytes, complement activation, oxidative killing or phagocytic uptake. Alternatively, they may redirect host defenses, such as fibrin formation or formation of neutrophil extracellular traps to favor pathogen replication. Thus, the response of *S. aureus* to the human immune system is highly flexible, allowing survival in the host’s hostile environment. Due to its adaptability *S. aureus* has also become resistant to a broad spectrum of antibiotics and nowadays the drug-resistant lineages of *S. aureus* have also become resistant to a broad spectrum of antibiotics. and represent a serious public health burden. This applies in particular to methicillin-resistant *S. aureus* (MRSA), which causes significantly increased morbidity and mortality worldwide. Vancomycin has been the drug of choice to treat MRSA infections, but strains have emerged that display reduced vancomycin susceptibility. This implies that there is an urgent need for new and reliable approaches to prevent and treat infections by drug-resistant staphylococci.

Immune therapies against *S. aureus* infections have been explored as a treatment alternative to antibiotics. While active immunization could potentially prevent the onset of *S. aureus* infections, passive immunization could be applied to treat acute or current infections. While the use of pooled human sera does not seem to be very effective, passive immunization with monoclonal antibodies, preferably human monoclonal antibodies (humAbs), is an attractive alternative option. Importantly, humAbs have a high specificity, their synthesis is relatively straightforward, and they have a long history of safe use. However, despite recent successes in animal...
models,13-15 the efficacy of passive immunization with humAbs has not yet been confirmed in clinical trials.11

Wounds of patients with the genetic blistering disease epidermolysis bullosa (EB) are highly susceptible to bacterial colonization.16 In a study by van der Kooi-Pol et al., it was documented that essentially all investigated EB patients with chronic wounds were heavily colonized with \textit{S. aureus}.17 Interestingly, it was noted that these patients did not frequently suffer from \textit{S. aureus} bacteremia, despite the impaired barrier function of the skin. Compared to healthy individuals, the plasma of EB patients contained significantly higher IgG1 and IgG4 levels, suggesting a potentially protective effect of antistaphylococcal antibodies against invasive staphylococcal infections.18,19 In a recent project, we therefore collected B-cells from donors with EB and applied them to develop of a set of fully human monoclonal antibodies against molecules exposed on the cell surface of \textit{S. aureus}.13-15 The present study was aimed at the characterization of one of these humAbs referred to as 6D4. In brief, our results show that the humAb 6D4 binds specifically to the staphylococcal complement inhibitor (SCIN), thereby inhibiting its activity. Furthermore, using 6D4, we show that cell surface binding of SCIN is enhanced in the presence of human serum.

**Results**

**Identification of a human monoclonal antibody that targets the staphylococcal complement inhibitor SCIN**

The humAb 6D4 was identified from a random screen of B-cells producing antibodies that bind to whole cells of \textit{S. aureus}. Consequently, the actual target of 6D4 was initially not known. To identify the antigen recognized by 6D4, immunoprecipitation experiments were performed. However, the subsequent Mass Spectrometric analysis of precipitated proteins yielded no conclusive identification of the respective antigen (not shown). As an alternative approach toward target identification, we performed a Western blotting analysis on cell surface proteins of different \textit{S. aureus} isolates. As expected, 6D4 bound to the immunoglobulin-binding proteins Spa (also known as protein A) and Sbi (Fig. 1A). In addition, 6D4 was found to bind a protein of 10–15 kDa that was present both in the cell and growth medium fractions of \textit{S. aureus} NCTC8325, its derivative NCTC8325 (\textit{ΔspaΔsbi}) and NCTC8325 (\textit{ΔpknB}) (Fig. 1A and B). The respective signal was however absent from samples of \textit{S. aureus} NCTC8325 (\textit{ΔpknBDF13}) (Fig. 1B) and \textit{S. aureus} SH1000 (not shown). The latter strains both lack the phage 13 (\textit{Φ13}).20 This suggested that the antigen recognized by 6D4 was most likely an exported protein of 10–15 kDa encoded by \textit{Φ13}. Indeed, \textit{Φ13} encodes 2 proteins, SCIN (13 kDa) and the Chemotaxis Inhibitory Protein of \textit{S. aureus} (CHIPS; 17 kDa), which are known to be exported from the cytoplasm to the extracellular milieu.

To test whether 6D4 binds to SCIN or CHIPS, the respective genes were cloned and expressed with a His-tag in \textit{Lactococcus lactis} strain PA1001. As shown by Western blotting with anti His-tag antibodies both SCIN and CHIPS were expressed and secreted by \textit{L. lactis} upon induction with nisin (Fig. 1C). Importantly, the humAb 6D4 was found to bind specifically to SCIN (Fig. 1D). We considered this an important observation as SCIN is a potent inhibitor of the human complement system.21-23

**HumAb 6D4 binds to the active site of SCIN**

To identify the specific SCIN epitope recognized by 6D4, we applied a set of previously constructed

![Figure 1. Identification of SCIN as target of humAb 6D4. Western blot analysis using humAb 6D4 on proteins from cell pellet (P) and growth medium fractions (supernatant; S) of the \textit{S. aureus} (5a) strains NCTC8325 and NCTC8325 \textit{ΔspaΔsbi} (A), and the growth medium fractions of strains NCTC8325 \textit{ΔpknB} and NCTC8325 \textit{ΔpknB Φ13} (B). Western blot analysis of the growth medium fractions of \textit{L. lactis} pNG4210:scn or pNG4210:chips secreting the SCIN or CHIPS proteins, respectively, using anti-His-tag antibodies (C), or humAb 6D4 (D). Molecular weights (kDa) of marker proteins are indicated next to panel A.](image-url)
**HumAb 6D4 specifically binds the S. aureus SCIN protein**

To verify the specificity of 6D4 for *S. aureus*, we performed a BLAST analysis using the NCBI protein database to identify other bacteria containing SCIN-encoding genes. This showed that the presence of SCIN was restricted to *S. aureus*, and that proteins with limited sequence similarity to SCIN were encoded by the genomes of only few other *Staphylococcus* species, including *S. argenteus* (61% identity from 89% query cover, GenBank: CDR22445.1), *S. hominis* (53% identity from 73% query cover, GenBank: EEK11996.1) and *S. haemolyticus* (57% identity from 74% query cover, GenBank: CPM70056.1). In none of these SCIN homologues was the epitope recognized by 6D4 (i.e. residues 26 to 36) fully conserved. This was confirmed by Western blotting analyses, where 6D4–800CW showed no binding to proteins from *S. hominis* or *S. haemolyticus*, while clear binding to the SCIN proteins of different sequenced *S. aureus* strains was detected (Fig. 3A). Of note, our BLAST analysis indicated that *S. aureus* COL does not contain the *scn* gene encoding SCIN and, consistent with this finding, 6D4–800CW did not bind to any protein of *S. aureus* COL (Fig. 3A).

**SCIN is detectable in most clinical S. aureus isolates**

To explore the production of SCIN by clinical isolates of *S. aureus*, this was assessed with 6D4–800CW in a set of 24 clinical *S. aureus* isolates from the University Medical Center Groningen of which 22 were previously shown by PCR to carry the *scn* gene. Intriguingly, Western blotting with 6D4–800CW revealed the presence of SCIN in 23 of the 24 tested isolates (Fig. 3B), including isolate G which had tested negative for *scn* in the previous PCR analysis. In contrast, isolate T which had also tested negative for *scn* in the previous PCR also tested negative in the Western blotting with 6D4–800CW. A renewed PCR using *scn*-specific primers showed that the *scn* gene was indeed present in isolate G (data not shown), which is
consistent with the detection of SCIN with 6D4–800CW in this isolate. Altogether, these results show that humAb 6D4 labeled with IRDye 800CW can be applied for the specific identification of clinical S. aureus isolates expressing SCIN.

Serum incubation increases binding of SCIN to S. aureus cells

The S. aureus SCIN protein specifically inhibits the human complement system, one of the most important components of the innate immune system.24,26-29 This is achieved through the binding of SCIN to the C3b moiety of human C3 convertases on the bacterial surface, leading to their stabilization in a catalytically inactive form and preventing enhanced conversion of C3 into C3b as part of the so-called ‘alternative pathway’ in innate immunity. In addition, SCIN promotes the formation of inactive convertase dimers that preclude C3b binding by the complement receptor of phagocytic cells.27,30 Because the C3 convertases are key initiators in the complement activation cascades, effector functions such as C3b-mediated phagocytosis and C5a-mediated cell recruitment are effectively prevented by SCIN.21,23,24,27-30

From the Western blotting analyses shown in Figs. 1 and 3, it was evident that SCIN is mostly detectable in growth medium fractions, and only to minor extent in the cell fractions when cells are grown in Tryptic Soy Broth (TSB). The latter is consistent with the previously documented finding that SCIN binds to the C3 convertases, which are formed on the S. aureus cell wall after initial C3b deposition.26 Therefore, we hypothesized that SCIN is likely more abundant in the cell fraction when cell wall-attached C3b is present. To verify this idea, S. aureus Newman ΔspaΔsbi cells were covered with C3b through incubation in human sera and, subsequently, these cells were incubated in the presence or absence of added SCIN. As reflected by 6D4–800CW binding upon Western blotting, cells not incubated in serum displayed low levels of SCIN, whereas the respective supernatant fractions yielded a high signal due to the presence of SCIN (Fig. 4). Similarly, the serum-incubated samples without added SCIN showed a low signal in both the cell- and the respective supernatant fractions. In contrast, the serum-incubated samples with added SCIN showed a high SCIN-specific signal in the cell fraction and a lowered signal in the supernatant fraction (Fig. 4). These results show that the enhanced SCIN binding to the S. aureus cell wall due to the deposition of C3b and C3 convertases is readily detectable with the 6D4–800CW humAb.
A plate assay was used to assess whether whole \textit{S. aureus} cells could be detected after incubation with human sera using 6D4–800CW. Indeed, 6D4–800CW was found to bind concentration-dependently to the \textit{S. aureus} clinical isolate P, and the strains USA300, Newman wild-type and Newman \(\Delta\text{spa}\Delta\text{sbi}\) (Fig. 5A). In this assay binding of 6D4 to Spa and Sbi via the Fc-region was blocked by the addition of unrelated rabbit IgG, and effective blocking was confirmed with a control His-tag-specific rabbit antibody (\(\alpha\)-his-tag; Fig. 5A). Importantly, 6D4–800CW allowed the detection of cell-bound SCIN in 19 of 24 clinical \textit{S. aureus} isolates tested (Fig. 5B) Here it is noteworthy that 5 isolates showed no enhanced binding of SCIN, including 4 \textit{scn}-proficient isolates and the isolate T lacking the \textit{scn} gene. Furthermore, 6D4–800CW allowed detection of cell-bound SCIN for 8 of 9 sequenced \textit{S. aureus} strains, where only the COL strain that lacks the \textit{scn} gene yielded no signal (Fig. 5B). Binding of the \(\alpha\)-his-tag control antibody was low for all strains due to blocking with an unrelated rabbit IgG (Fig. 5B).

**Direct detection of SCIN bound to the surface of \textit{S. aureus} cells**

For direct detection of SCIN bound to the surface of \textit{S. aureus} cells, samples of \textit{S. aureus} Newman \(\Delta\text{spa}\Delta\text{sbi}\) were prepared and spotted onto glass slides for fluorescence microscopy at 800 nm. \textit{S. aureus} cells grown under standard culturing conditions and incubated with 6D4–800CW displayed almost no fluorescence and individual cells could not be distinguished (Fig. 6, A and B). Further, cells incubated in
serum, but lacking added SCIN, showed no fluorescent signal at all (Fig. 6, C and D). Importantly however, serum-incubated cells with added SCIN showed a strongly enhanced fluorescent signal at 800 nm (Fig. 6, E and F). Here individual cells were detectable, though it is noteworthy that not all cells appeared to be fluorescently tagged. Taken together, these observations show that *S. aureus* cells incubated with human serum have a high potency for binding of SCIN, most likely due to the deposition of C3b and C3 convertases, which can be detected with IRDye 800CW-labeled 6D4 humAb.

**Impact of 6D4 on SCIN activity**

Since the humAb 6D4 binds to the active site of SCIN, we asked the question how this antibody impacts on the deposition of C3b on the *S. aureus* cell surface. To this end, we used an assay where increasing amounts of SCIN were pretreated with 6D4, before mixing with human serum. As controls, the SCIN protein was mock-treated with buffer or a control IgG before mixing with serum. Next, *S. aureus* Newman ΔspaΔsbi cells were incubated for 30 min with the serum containing SCIN (with or without 6D4 pretreatment), after which the presence of C3b on the staphylococcal cell surface was measured by flow cytometry. As shown in Fig. 7A, in this assay the preincubation of SCIN with humAb 6D4 resulted in a relative deposition of C3b on the *S. aureus* cells close to 1, which represents the maximal C3b deposition upon incubation with serum. In contrast, the C3b deposition was inhibited by SCIN in the absence of 6D4. These findings imply that 6D4...
can interfere with the deposition of C3b on the S. aureus cells.

An alternative possibility to measure the impact of 6D4 on SCIN activity is provided by the fact that complement causes the lysis of rabbit erythrocytes, and that this hemolysis can be inhibited by SCIN. To assess whether SCIN-mediated inhibition of the alternative pathway’s hemolytic activity can be suppressed by 6D4, we pre-treated increasing amounts of SCIN with 6D4, before mixing with human serum and erythrocytes. As a negative control, the SCIN protein was either mock-treated with buffer or a control IgG before mixing with serum and erythrocytes. Next, the erythrocytes were incubated for 60 min with the human serum containing SCIN (with or without 6D4 pre-treatment), after which the erythrocytes were pelleted and the absorbance of supernatants at 450 nm was measured to assess the erythrocyte lysis. As shown in Fig. 7B, the preincubation of SCIN with 6D4 significantly reduced the protective effect of SCIN with respect to erythrocyte lysis, as compared with SCIN preincubated with the control IgG or with buffer. These observations fully support the view that the activity of SCIN can be inhibited by the humAb 6D4.

Discussion

In this study, we show that the humAb 6D4 binds to the first α-helix of the staphylococcal complement inhibitor SCIN, which covers part of this protein’s active site domain. Consistent with this finding, 6D4 interferes with the activity of SCIN, as shown through the analysis of C3b deposition on S. aureus cells and suppression of the protective effect of SCIN in the alternative pathway-mediated hemolysis of rabbit erythrocytes. Furthermore, we show that 6D4 labeled with the near-infrared fluorophore IRDye 800CW can be readily used to visualize the production and subcellular localization of SCIN by S. aureus.

The analysis of publicly available bacterial genome sequences suggests that the scn gene is specific for S. aureus isolates causing infections in humans. While sequenced S. hominis and S. haemolyticus strains contain genes with some sequence similarity to the S. aureus scn gene, the tested S. hominis and S. haemolyticus strains did not bind humAb 6D4. This underpins the conclusion that this humAb is highly specific for S. aureus SCIN, and suggests that it will bind preferentially to isolates associated with infections in humans. Previous studies have reported that SCIN may be present in 90% of all clinical S. aureus isolates and that it is expressed in vivo.21-24 Consistent with this view, we observed that, from a panel of 33 tested S. aureus isolates, only 2 did not express SCIN.

SCIN is a potent antigen that evokes high antibody titres in S. aureus-colonized individuals.18,31,32 Under the in vitro conditions used for culturing S. aureus in this study, the clearest SCIN signals were obtained for growth medium fractions, while the signals in the respective S. aureus cell fractions were relatively low. On the other hand, our present findings...
show that SCIN was effectively recruited to the \textit{S. aureus} cell surface when this bacterium was exposed to human serum. This phenomenon was also clearly evident at the single cell level by fluorescence microscopy. The observed redistribution of SCIN is consistent with the fact that SCIN binds to the C3b moiety of C3 convertases upon their deposition on the bacterial cell surface.\textsuperscript{33} This puts emphasis on the extensive interactions between \textit{S. aureus} and its human host, which are underestimated under the generally applied \textit{in vitro} culturing conditions. Indeed this view is confirmed by a previous study showing that \textit{S. aureus} cells bind a variety of human proteins to their cell surface upon incubation in plasma.\textsuperscript{34} Of note, when serum-incubated clinical \textit{S. aureus} isolates and laboratory strains were tested for enhanced binding of SCIN using 6D4–800CW, only 4 out of 34 investigated strains remained undetectable, which suggests that they only bind small amounts of SCIN. Notably, our Western blotting analyses show that these strains produce relatively low amounts of SCIN, which might not be sufficient to distinguish the SCIN-specific signal from the background signal in a whole cell plate reader-based approach. Of note, upon fluorescence microscopy, not all \textit{S. aureus} cells appeared to bind equal amounts of 6D4–800CW, suggesting that there may be cell-to-cell differences in the formation of C3 convertases, the binding of SCIN or the binding of 6D4–800CW.

In conclusion, in the present study we present a humAb that binds to the active site of the \textit{S. aureus} SCIN protein, especially residues 26-36. While the humAb 6D4 does interfere with the activity of SCIN, it seems rather unlikely that it can be applied in anti-staphylococcal therapy since SCIN-deficient variants of \textit{S. aureus} can cause infections. Importantly however, the IRDye 800CW-labeled version of this humAb (i.e., 6D4–800CW) can be applied to specifically detect \textit{S. aureus} isolates that express SCIN, an important virulence factor that allows \textit{S. aureus} to effectively evade the human complement system. A completely novel finding is that SCIN binding to the staphylococcal cell-surface is substantially enhanced in the presence of human serum. Since SCIN production is associated in particular with \textit{S. aureus} isolates that caused infections in humans, our SCIN-specific antibody may find potential future applications in the identification of \textit{S. aureus} lineages with a high potential for causing infections. This could not only involve diagnostic tests, but also \textit{in vivo} imaging approaches for which proof-of-principle was recently obtained using vancomycin labeled with the IRDye 800CW.\textsuperscript{35-37}

### Materials and methods

#### Strains and growth conditions

Strains used in this study are listed in Table 1. \textit{E. coli} Rosetta Gami (DE3) pLysS strains (Novagen, Merck Biosciences Darmstadt, Germany) carrying prSETB-derived plasmids with the genes encoding for SCIN, OrfD or the respective chimeric constructs have been described previously.\textsuperscript{24} \textit{E. coli} Rosetta gami strains were grown overnight in Lysogeny Broth (LB, Becton Dickinson, Breda, The Netherlands) at 37°C under vigorous agitation (250 rpm), in the presence of ampicillin (50 \textmu g/ml) and chloramphenicol (34 \textmu g/ml) for plasmid selection. All staphylococcal strains were cultured overnight in TSB (Oxoid Limited, Hampshire, UK) at 37°C under vigorous agitation (250 rpm), unless otherwise specified. \textit{L. lactis} strains were grown at 30°C in M17 broth (Oxoid Limited), or on plates containing 1.5% agar and 0.5% glucose (wt/vol), supplemented with chloramphenicol (5 \textmu g/ml) for plasmid selection.

#### Sample preparation, SDS/LDS-PAGE, western blotting and immunodetection

For the production of chimera of SCIN and the homologous OrfD protein of unknown function overnight cultures of described previously \textit{E. coli} Rosetta gami strains\textsuperscript{24} were diluted to an optical density at 600nm (OD\textsubscript{600}) of 0.1. Chimeric protein production was induced at an OD\textsubscript{600} of ~0.5 by the addition of 1 mM isopropyl-\textbeta-D-thiogalactopyranoside (IPTG). After 4 h of continued cultivation, cells were collected by centrifugation, and the SCIN-OrfD chimeras produced by these cells were separated by SDS-PAGE as described previously.\textsuperscript{24} The replacement of SCIN residues with corresponding OrfD residues is detailed in Fig. 2 and the corresponding legend.

For the preparation of LDS-PAGE samples, \textit{S. aureus} cells collected by centrifugation were disrupted with 0.1 \mu m glass beads (Biospec Products, Bartlesville, USA) in a Precellys 24 homogenizer (Bertin Technologies, France), and resuspended in LDS sample buffer (Life Technologies). Growth medium fractions were prepared for LDS-PAGE as described before\textsuperscript{1} Proteins were separated on NuPAGE gels (Life Technologies) and either visualized by Simply Blue Safe Staining (Life Technologies)\textsuperscript{1} or Western blotting using either mouse anti-His tag (Life Technologies), IRDye 800CW-labeled humAb 6D4, or IRDye 800CW-labeled secondary goat anti-human or goat anti-mouse antibodies (LI-COR Biosciences). Bound antibodies were visualized using an Odyssey Infrared Imaging System (LI-COR Biosciences).
Miniprep Kit (Zymo Research Corporation, USA) following the manufacturer’s protocol. Primer pairs Scin-up/Scin-low used for detection of *scn*, the gene encoding SCIN, were used as described previously. Cloning of the PCR-amplified *scn* and *chp* genes was performed by *Not*I and *Bam*HI (New England Biolabs) cleavage followed by ligation to *Not*I/*Bam*HI cleft plasmid pNG4210. Ligated mixtures were used to transform electrocompetent *L. lactis* PA1001 as described. All constructs thus obtained were verified by sequencing (Eurofins MWG Operon, Ebersberg, Germany).

The production of secreted SCIN and CHIPS in exponentially growing (~0.5 OD_{600}) cultures of *L. lactis* was induced by the addition of nisin (3 ng/ml, Sigma-Aldrich, St. Louis, MO). Growth medium fractions were harvested after overnight incubation at 30°C, and proteins in these fractions were analyzed by LDS-PAGE, Simply Blue Safe Staining, or Western blotting as described above.

### S. aureus incubation in human sera

Cells of *S. aureus* Newman Δ*spaΔubi* were collected from the growth medium by centrifugation at 14,000 rpm for 2 min. The supernatant fraction, containing secreted SCIN, was collected. Next, the collected cells were resuspended and incubated with 20% human serum in HBS (Hepes Buffered Saline; 20mM Hepes, 140 mM NaCl) plus 5 mM CaCl₂ and 2.5 mM MgCl₂ for 30 min to coat the bacteria with C3B and allow for the formation of C3 convertases. Subsequently, the cells were incubated in PBS at 37°C for 30 min to dissociate surface-attached C2a/Bb. Where appropriate, the collected *S. aureus* supernatant was added to the C3 convertase-covered bacteria to allow binding of SCIN to the surface-attached C3 convertase. The protocol for blood donations from healthy volunteers was approved by the Independent Ethics Committee of the Foundation ‘Evaluation of Ethics in Biomedical Research’ (Assen, the Netherlands). This protocol is registered by QPS Groningen (code 04132-CS011). The required written consent was obtained for all donors included in the present studies.

### Expression of staphylococcal SCIN and CHIPS proteins in *L. lactis*

Primers used for cloning are described in Table 2. DNA amplification was performed using Fusion Hot start High-Fidelity DNA polymerase according the instructions of the supplier (Thermoscientific). Bacterial chromosomal DNA was isolated using the ZR BAC DNA

### Table 1. Strains and plasmids used in this study.

| Strains | Relevant phenotype(s) or genotype(s) | Reference or Source |
|---------|-------------------------------------|---------------------|
| *S. aureus* Newman | NCT8178 clinical isolate | 40 |
| *S. aureus* Newman | spa sbi mutant | 41 |
| *S. aureus* USA300 | Community-acquired MRSA isolate | 42 |
| *S. aureus* SH1000 | rsbU*, agr*; replacement of spa by kanamycin resistance marker (KanR) | 1 |
| *S. aureus* N315 | Hospital-acquired MRSA isolate | 43 |
| *S. aureus* NCTC8325 ΔpknB | NCTC8325 (wild-type, 11-bp deletion in rsbU) containing *pknB* deletion | 44 |
| *S. aureus* NCTC8325 ΔpknB ΔΦ13 | NCTC8325 ΔpknB that had lost the phage 13 | 45 |
| *S. aureus* NCTC8325ΔspaΔubi | spa sbi mutant | 42 |
| *S. aureus* NCTC8325Δ4 | Prophage cured and restriction-deficient derivative of NCTC 8325 | 46 |
| *S. aureus* Mu50 | Hospital-acquired vancomycin-resistant isolate | 43 |
| *S. aureus* MW2 | Community-acquired MRSA isolate | 47 |
| *S. aureus* COL | Early hospital-acquired MRSA isolate | 48 |
| *S. aureus* MRSA252 | Hospital-acquired MRSA isolate | 49 |
| *S. aureus* M55A476 | Community-acquired methicillin-sensitive isolate | 49 |
| *S. aureus* isolates A-J and L-Y | Community- and hospital-acquired clinical isolates collected during a 4.5-year period in the UMCG from 19 patients with different clinical symptoms for detailed strain descriptions see reference) | 25 |
| *S. haemolyticus* | Opportunistic pathogen clinical strain from UMCG | This study |
| *S. hominis* | Human commensal strain obtained from UMCG | This study |
| *E. coli* Rosetta gami (DE3) pLysS | DE3 lysogen contains T7 polymerase upon IPTG induction. | (Novagen) |
| *L. lactis* PA1001 | MG1363 pepN::nisIK, ΔacmA ΔhtrA | 50 |

### Table 2. Primers used for detection or cloning of *scn* and *chp* genes.

| Primer | Sequence 5’ → 3’ | Enzyme |
|--------|------------------|--------|
| Scn F | ATATGGATCCCAACAGCTGCGACAATCGAATGAATATCGAATGAATGAATATC | BamHI |
| Scn R | ATATCGGCCCCTTTTATTTTTAGTTTGGCTTGTCAATTTC | NotI |
| Chp F | ATATGGATCCCATTTTATTTTTAGTTTGGCTTGTCAATTTC | BamHI |
| Chp R | ATATCGGCCCCTTTTATTTTTAGTTTGGCTTGTCAATTTC | NotI |
| Scin-up | AGCTTTTTAAGCTTAAGAGCG | | |
| Scin-low | GTTTAGCATCACCACACTAGTA | |

Notes: * restriction enzyme sites are underlined in the nucleotide sequences.

---

**Expression of staphylococcal SCIN and CHIPS proteins in *L. lactis***

Primers used for cloning are described in Table 2. DNA amplification was performed using Fusion Hot start High-Fidelity DNA polymerase according the instructions of the supplier (Thermoscientific). Bacterial chromosomal DNA was isolated using the ZR BAC DNA...
Detection of SCIN bound to whole cells of *S. aureus*

*S. aureus* isolates were grown overnight in TSB, diluted 1:100 in fresh medium and cultured until the mid-exponential growth phase (OD$_{600}$ ~0.5). Next, the cells were coated with complement by adding serum (end concentration 20%) and incubation was continued for 30 min. After this incubation, the bacteria were washed with phosphate-buffered saline (PBS). High-binding ELISA plates for fluorescence measurements (Greiner Bio-one) were coated with $5 \times 10^6$ colony forming units (CFU) per well in PBS for 18 h at 4°C. Plates were blocked with 4% BSA in PBS with 0.05% Tween-20 (PBST). Surface-bound IgG Fc-binding proteins of *S. aureus* (i.e., Spa and Sbi) were saturated with 100 $\mu$g/mL normal rabbit immunoglobulin fraction (DAKO) in PBST containing 1% BSA. The humAb 6D4 was labeled with IRDye 800CW (LI-COR Biosciences, Bad Homburg, Germany) by incubation for 2 hours with 20 $\mu$g of IRDye 800CW per mg of protein in PBS (pH 8.5). The mix was desalted by incubation for 2 hours with 20 $\mu$l of IRDye G-25 desalting column (GE Healthcare, Germany). The resulting 6D4–800CW was stored in the dark at 4°C. To quantify the binding of 6D4–800CW to serum-incubated whole cells with added SCIN, the plates were incubated with 300 ng/mL 6D4–800CW in PBS for 30 min, washed thrice with PBS and scanned with the Odyssey infrared imaging system (Li-Cor Biosciences) for fluorescence at 800 nm.

Fluorescence microscopy

Overnight cultures in TSB were diluted to an OD$_{600}$ of 10. Untreated samples were taken from the overnight culture. Convertase-covered cell samples were obtained as described above. Cells were collected by centrifugation at 14,000 rpm for 2 min and washed with PBS. The washed cells were incubated with the 6D4–800CW (3000 ng/mL in PBS) for 30 min. After the incubation, the cells were collected by centrifugation at 14,000 rpm for 2 min and washed with PBS. Next, cells were spotted on a glass slide for microscopy, and a coverslip was mounted and sealed. Fluorescence microscopy was performed using a Leica DM5500B epifluorescence microscope equipped with an 800 nm filter block. Images were captured with a Leica DFC365FX camera using a 63x objective (Leica Microsystems BV, The Netherlands).

Determination of C3b deposition on *S. aureus* cells

Cells of *S. aureus* Newman ΔspaΔsbi were collected as described above, and $5 \times 10^7$ CFU/ml were incubated with 5% pooled normal human serum in HBS plus 5 mM CaCl$_2$, 2.5 mM MgCl$_2$ and 0.1% human serum albumin for 30 min at 37°C while shaken at 700 rpm. Different concentrations SCIN (0–4 $\mu$g/ml) were preincubated with the purified humAb 6D4 (10 $\mu$g/ml), with the control human anti-DNP IgG1 (10 $\mu$g/ml, Genmab, Utrecht), or with HBS buffer for 10 min at room temperature before mixing with the serum. Bacteria were washed by centrifugation and incubated with 1 $\mu$g/ml anti-C3b mAb (Quidel Corp.) for 30 min at 4°C followed by APC-labeled Goat-anti-Mouse-Ig (BD Biosciences). Samples were fixed with 1% paraformaldehyde (Polysciences) and analyzed on a FACSVerse flow cytometer (BD Biosciences). Data are expressed relative to the mean fluorescence value of bacteria incubated in serum only.$^{23}$

The alternative pathway hemolytic assay

Washed rabbit erythrocytes at $1 \times 10^6$ c/ml (Biotrading) were incubated with 5% pooled normal human serum in HBS plus 10 mM MgCl$_2$ and 10 mM EGTA for 60 min at 37°C while shaken at 600 rpm. Different concentrations SCIN were preincubated with purified humAb 6D4 (10 $\mu$g/ml), with the control human anti-DNP IgG1 (10 $\mu$g/ml, Genmab, Utrecht), or with HBS-buffer plus 10 mM MgCl$_2$ and 10 mM EGTA for 10 min at room temperature before mixing with serum. Erythrocytes were pelleted and the absorbance of supernatants at 450 nm was measured. Data are expressed relative to the mean value measured for erythrocytes incubated with serum only, which was set to 1.$^{21}$

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Martin van der Heide and Tim van der Toorn for technical support and Annette Dreisbach for helpful discussions.

Funding

Part of this research was supported by the Top Institute Pharma projects T4–213. F. Romero Pastrana received a scholarship from CONACyT (169643).

References

[1] Sibbald MJJB, Yang X-M, Tsompanidou E, Qu D, Hecker M, Becher D, Buist G, van Dijl JM. Partially overlapping substrate specificities of staphylococcal group A sortases.
PROTEOMICS 2012; 12:3049-62; PMID:22930668; https://doi.org/10.1002/pmic.201200144

[2] Stefani S, Goglio A. Methicillin-resistant staphylococcus aureus: Related infections and antibiotic resistance. Int J Infect Dis 2010; 14(Supplement 4):S19-22; PMID:20843722; https://doi.org/10.1016/j.ijid.2010.05.009

[3] Thammavongsa V, Kim HK, Misiakas D, Schneewind O. Staphylococcal manipulation of host immune responses. Nat Rev Microbiol 2015; 13:529-43; PMID:26272408; https://doi.org/10.1038/nrmicro3521

[4] Stryjewski ME, Corey GR. Methicillin-resistant staphylococcus aureus: An evolving pathogen. Clin Infect Dis 2014; 58:S10-9; PMID:24343827; https://doi.org/10.1093/cid/cit613

[5] Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Stefani S, Goglio A. Methicillin-resistant staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26:166-74; PMID:15756888; https://doi.org/10.1086/505252

[6] Mulher WP, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2006–2007. Infect Control Hosp Epidemiol 2008; 29:996-1011; PMID:18947320; https://doi.org/10.1086/591861

[7] Moeller RC, Jr. The growing menace of community-acquired methicillin-resistant staphylococcus aureus. Ann Intern Med 2006; 144:368-70; PMID:16520479; https://doi.org/10.1086/502522

[8] Holmes NE, Johnson PDR, Howden BP. Relationship between vancomycin-resistant staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol 2012; 50:2548-52; PMID:22593595; https://doi.org/10.1128/JCM.00775-12

[9] Rupp ME, Holley HP, Lutz J, Dicpinigaitis PV, Woods C, Levine DP, Veney N, Fowler VG. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-staphylococcus aureus capsular polysaccharide immune globulin in treatment of staphylococcal bacteremia. Hum Vaccines Immunother 2014; 10:926-37; PMID:24495867; https://doi.org/10.1128/HV.027692

[10] van der Kooi-Pol MM, Duipmans JC, Jonkman MF, van Dijl JM. Host-pathogen interactions in epidermolysis bullosa patients colonized with Staphylococcus aureus. Int J Med Microbiol IJMM 2014; 304:195-203; PMID:24444717; https://doi.org/10.1016/j.ijmm.2013.11.012

[11] van der Kooi-Pol MM, Veenstra-Kyuchukova YK, Duipmans JC, Pluister GN, Schouls LM, de Neeling AJ, Grundmann H, Jonkman MF, van Dijl JM. High genetic diversity of Staphylococcus aureus strains colonizing patients with epidermolysis bullosa. Exp Dermatol 2012; 21:463-6; PMID:22621190; https://doi.org/10.1111/j.1600-0625.2012.01502.x

[12] van der Kooi-Pol MM, de Vogel CP, Westerhout-Pluister GN, Veenstra-Kyuchukova YK, Duipmans JC, Pluister GN, Schouls LM, de Neeling AJ, Verkaik N, Ramdani-Bouguessa N, Jonkman MF, et al. High anti-staphylococcal antibody titers in patients with epidermolysis bullosa relate to long-term colonization with alternating types of staphylococcus aureus. J Invest Dermatol 2013; 133:847-50; PMID:23014336; https://doi.org/10.1038/jid.2012.347

[13] Swierstra J, Debets S, de Vogel C, Lemmens-den Toorn N, Verlaak N, Ramdani-Bouguessa N, Jonkman MF, van Dijl JM, Fahal A, van Belkum A, et al. IgG4 subclass-specific responses to staphylococcus aureus antigens shed new light on host-pathogen interaction. Infect Immun 2015; 83:492-501; PMID:25404029; https://doi.org/10.1128/IAI.02266-14

[14] O’Neill AJ. Staphylococcus aureus SH1000 and 8325-4: Comparative genome sequences of key laboratory strains in staphylococcal research. Lett Appl Microbiol 2010; 51:358-61; PMID:20618890; https://doi.org/10.1111/j.1477-765X.2010.02885.x

[15] Jongerius I, Köhl J, Pandey MK, Ruyken M, van Kessel KPM, van Strijp JAG, Rooijakkers SHM. Staphylococcal complement evasion by various convertase-blocking molecules. J Exp Med 2007; 204:2461-71; PMID:17893203; https://doi.org/10.1084/jem.20070818

[16] van Wamel WJB, Rooijakkers SHM, Ruyken M, van Kessel KPM, van Strijp JAG. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of staphylococcus aureus are located
on β-hemolysin-converting bacteriophages. J Bacteriol 2006; 188:1310-5; PMID:16452413; https://doi.org/10.1128/JB.188.1310-1315.2006

[23] Rooijakkers SHM, Ruyken M, Roos A, Daha MR, Presanis JS, Sim RB, van Wamel WJB, van Kessel KPM, van Strijp JAG. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol 2005; 6:920-7; PMID:16086019; https://doi.org/10.1038/ni1235

[24] Rooijakkers SHM, Milder FJ, Bardool EW, Ruyken M, van Strijp JAG, Gros P. Staphylococcal complement inhibitor: Structure and active sites. J Immunol 2007; 179:2989-98; PMID:17709514; https://doi.org/10.4049/jimmunol.179.5.2989

[25] Ziebandt A-K, Kusch H, Degner M, Jaglitz S, Sibbald MJJB, Arends JP, Chlebowicz MA, Albrecht D, Pantucek R, Doskar J, et al. Proteomics uncovers extreme heterogeneity in the staphylococcus aureus exoproteome due to genomic plasticity and variant gene regulation. PROTEOMICS 2010; 10:1634-44; PMID:20186749; https://doi.org/10.1002/pmic.200900313

[26] Serruto D, Rappuoli R, Scarselli M, Gros P, van Strijp JAG. Molecular mechanisms of complement evasion: learning from staphylococi and meningococci. Nat Rev Microbiol 2010; 8:393-9; PMID:20467445; https://doi.org/10.1038/nrmicro2366

[27] Jongerius I, Puister M, Wu J, Ruyken M, van Strijp JAG, Rooijakkers SHM. Staphylococcal complement inhibitor modulates phagocyte responses by dimerization of convertases. J Immunol 2010; 184:420-5; PMID:19949103; https://doi.org/10.4049/jimmunol.0902865

[28] Garcia BL, Ramyar KX, Ricklin D, Lambris JD, Geisbrecht BV. Advances in understanding the structure, function, and mechanism of the SCIN and Elb families of staphylococcal immune evasion proteins. Adv Exp Med Biol 2012; 946:113-33; PMID:21948365; https://doi.org/10.1007/978-1-4614-0106-3_7

[29] Garcia BL, Summers BJ, Ramyar KX, Tzekou A, Lin Z, Ricklin D, Lambris JD, Laity JH, Geisbrecht BV. A structurally dynamic N-terminal helix is a key functional determinant in staphylococcal complement inhibitor (SCIN) proteins. J Biol Chem 2013; 288:2870-81; PMID:23233676; https://doi.org/10.1074/jbc.M112.426858

[30] Rooijakkers SHM, Wu J, Ruyken M, van Domelselaar R, Planken KL, Tzekou A, Ricklin D, Lambris JD, Janssen BJC, van Strijp JAG, et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilised by a staphylococcal inhibitor. Nat Immunol 2009; 10:721-7; PMID:19503103; https://doi.org/10.1038/ni.1756

[31] van den Berg S, Bowden MG, Bosma T, Buist G, van Dijl JM, van Wamel WJ, de Vogel CP, van Bakelum A, Bakker-Woudenberg IAJM. A multiplex assay for the quantification of antibody responses in staphylococcus aureus infections in mice. J Immunol Methods 2011; 365:142-8; PMID:21185300; https://doi.org/10.1016/j.jim.2010.12.013

[32] Glasner C, van Timmeren MM, Stobernack T, Omansen TF, Raangs EC, Rossen JW, de Goffau MC, Arends JP, Kampinga GA, Koedijk DGAM, et al. Low anti-staphylococcal IgG responses in granulomatous with polyangiitis patients despite long-term staphylococcus aureus exposure. Sci Rep [Internet] 2015 [cited 2015 Feb 27]; 5:8188. Available from: http://www.nature.com/srep/2015/150202/srep08188/full/srep08188.html; PMID:25641235; https://doi.org/10.1038/srep08188

[33] Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol [Internet] 2015 [cited 2016 May 31]; 6:262. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451739/; PMID:26082779; https://doi.org/10.3389/fimmu.2015.00262

[34] Dreisbach A, van der Kouoi-Pol MM, Otto A, Gronau K, Bonarius HPJ, Westra H, Groen H, Becher D, Hecker M, van Dijl JM. Surface shaving as a versatile tool to profile global interactions between human serum proteins and the staphylococcus aureus cell surface. Proteomics 2011; 11:2921-30; PMID:21674804; https://doi.org/10.1002/pmc.201100134

[35] van Oosten M, Schäfer T, Gazendam JAC, Ohsken S, Tsompanidou E, de Goffau MC, Harmen SJM, Crane LMA, Lim E, Francis KP, et al. Real-time in vivo imaging of invasive- and biomaterial-associated bacterial infections using fluorescently labelled vancomycin. Nat Commun 2013; 4:2584; PMID:24129412; https://doi.org/10.1038/ncomms3584

[36] van Oosten M, Hahn M, Crane LMA, Pleijhuis RG, Francis KP, van Dijl JM, van Dam GM. Targeted imaging of bacterial infections: Advances, hurdles and hopes. FEMS Microbiol Rev 2015; 39:892-916; PMID:26109599; https://doi.org/10.1093/femsre/fuv029

[37] Heuker M, Gomes A, van Dijl JM, van Dam GM, Friedrich AW, Sinha B, van Oosten M. Preclinical studies and prospective clinical applications for bacteria-targeted imaging: The future is bright. Clin Transl Imaging 2016; 4:253-64; PMID:27512688; https://doi.org/10.1007/s00336-016-0190-y

[38] Neef J, Milder FJ, Koedijk DGAM, Klaassens M, Heezius EC, van Strijp JAG, Otto A, Becher D, van Dijl JM, Buist G. Versatile vector suite for the extracytoplasmic production and purification of heterologous his-tagged proteins in lactococcus lactis. Appl Microbiol Biotechnol 2015; 99(21): 9037-48; https://doi.org/10.1007/s00253-015-6778-8

[39] Leenhouts K, Venema G. Lactococcal plasmid vectors. In KG Hardy, (ed.). Plasmids, a practical approach. Oxford, UK: Oxford University Press; 1993. pp. 65-94.

[40] Duthie ES, Lorenz LL. Staphylococcal coagulase: Mode of action and antigenicity. J Gen Microbiol 1952; 56:95-107.

[41] van Dijl JM, Buist G. Versatile vector suite for the extracytoplasmic production and purification of heterologous his-tagged proteins in lactococcus lactis. Appl Microbiol Biotechnol 2015; 99(21): 9037-48; https://doi.org/10.1007/s00253-015-6778-8

[42] McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. Pulsed-field gel electrophoresis typing of oxacillin-resistant staphylococcus aureus isolates from the United States: Establishing a national database. J Clin Microbiol 2003; 41:5113-20; PMID:14605147; https://doi.org/10.1128/JCM.41.11.5113-5120.2003
[43] Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, et al. Whole genome sequencing of meticillin-resistant staphylococcus aureus. The Lancet 2001; 357:1225-40; PMID:11418146; https://doi.org/10.1016/S0140-6736(00)04403-2

[44] Donat S, Streker K, Schirmeister T, Rakette S, Stehle T, Liebeke M, Lalk M, Ohlsen K. Transcriptome and functional analysis of the eukaryotic-type serine/threonine kinase PknB in staphylococcus aureus. J Bacteriol 2009; 191:4056-69; PMID:19376851; https://doi.org/10.1128/JB.00117-09

[45] Miller M. Mapping the interactions between staphylococcus aureus and host immune cells. [PHD thesis]. Groningen: s.n., 2012. 176 p.

[46] Kreiswirth BN, Löfdahl S, Betley MJ, O’Reilly M, Schlievert PM, Bergdoll MS, Novick RP. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 1983; 305:709-12; PMID:6226876; https://doi.org/10.1038/305709a0

[47] Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, Nagai Y, Iwama N, Asano K, Naimi T, et al. Genome and virulence determinants of high virulence community-acquired MRSA. The Lancet 2002; 359:1819-27; PMID:12044378; https://doi.org/10.1016/S0140-6736(02)08713-5

[48] Gill SR, Fouts DE, Archer GL, Mongodin EF, DeBoy RT, Ravel J, Paulsen IT, Kolonay JF, Brinkac L, Beanan M, et al. Insights on evolution of virulence and resistance from the complete genome analysis of an early meticillin-resistant staphylococcus aureus strain and a biofilm-producing meticillin-resistant staphylococcus epidermidis strain. J Bacteriol 2005; 187:2426-38; PMID:15774886; https://doi.org/10.1128/JB.187.7.2426-2438.2005

[49] Holden MTG, Feil EJ, Lindsay JA, Peacock SJ, Day NPJ, Enright MC, Foster TJ, Moore CE, Hurst L, Atkin R, et al. Complete genomes of two clinical staphylococcus aureus strains: Evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci USA 2004; 101:9786-91; PMID:15213324; https://doi.org/10.1073/pnas.0402521101

[50] Bosma T, Kanninga R, Neef J, Audouy SAL, van Roosmalen ML, Steen A, Buist G, Kok J, Kuipers OP, Robillard G, et al. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl Environ Microbiol 2006; 72:880-9; PMID:16391130; https://doi.org/10.1128/AEM.72.1.880-889.2006